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Abstract
Cancer chemotherapy efficacy is frequently impaired 
by either intrinsic or acquired tumor resistance. A fun-
damental problem in cancer research is identifying the 
cell type that is capable of sustaining neoplastic growth 
and its origin from normal tissue cells. In recent years, 
the cancer stem cell (CSC) theory has changed the 
classical view of tumor growth and therefore the thera-
peutic perspective. Overcoming intrinsic and acquired 
resistance of cancer stem/progenitor cells to current 
clinical treatments represents a major challenge in 
treating and curing the most aggressive and metastatic 
cancers. On the other hand, the identification of CSCs 
in vivo  and in vitro  relies on specific surface markers 
that should allow the sorting cancer cells into pheno-
typically distinct subpopulations. In the present re-
view, recent papers published on CSCs in solid tumors 
(breast, prostate, brain and melanoma) are discussed, 
highlighting critical points such as the choice of mark-
ers to sort CSCs and mouse models to demonstrate 
that CSCs are able to replicate the original tumor. A 
discussion of the possible role of aldehyde dehydro-
genase and CXCR6 biomarkers as signaling molecules 
in CSCs and normal stem cells is also discussed. The 
author believes that efforts have to be made to inves-
tigate the functional and biological properties of puta-
tive CSCs in cancer. Developing diagnostic/prognostic 
tools to follow cancer development is also a challenge. 
In this connection it would be useful to develop a mul-
tidisciplinary approach combining mathematics, phys-
ics and biology which merges experimental approaches 
and theory. Biological models alone are probably un-
able to resolve the problem completely.
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INTRODUCTION
Cancer stem cells (CSCs) are a subpopulation of  tumor 
cells that possess the stem cell properties of  self  renewal 
and differentiation, generating the heterogeneous lineages 
of  cancer cells that comprise the tumor. Thus, CSCs can 
only be defined experimentally by their ability to repli-
cate the generation of  a continuously growing tumor. 
Contrary to normal stem cells which are notable for the 
vigilance with which their proliferation is controlled and 
the care with which their genomic integrity is maintained, 
CSCs are frequently distinguished by their lack of  con-
trol of  such processes. Identifying differences between 
normal stem cells and CSCs is important for understand-
ing how cancers progress and for translating advances in 
CSC biology into therapies that help patients.
There are many issues related to the identification 
of  CSCs that must be considered. The first is the use of  
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serial transplantation to validate a candidate CSC sub-
population, monitoring its capability to reproduce the 
heterogeneity of  the primary tumor. Both xeno- and syn-
geneic transplantation may lose the intricate network of  
interactions with diverse support, such as those involving 
fibroblasts, endothelial cells, macrophages, mesenchymal 
stem cells, as well many of  the cytokines and receptors 
involved in these interactions (for a more comprehensive 
discussion reed[1]). Another important problem is deter-
mining the best markers to identify CSCs. As discussed 
below this problem is still open. In light of  recent find-
ings reported for solid tumors like brain, prostate, breast 
and melanoma, I give my point of  view on this issue. 
Moreover I discuss how to dissipate the shadows from 
the CSCs debate. 
CSCs IN SOLID TUMORS: BREAST, 
PROSTATE, BRAIN AND MELANOMA
Tumor growth can be described either by the conven-
tional model or by the CSC theory. According to the first 
model, cells are homogeneous and all are tumorigenic, 
while the CSC theory states that in the tumor there is a 
subpopulation sustaining tumor growth[1]. The first evi-
dence of  CSCs came from hematological tumors such 
as acute myeloid leukemia[2]. Later, CSCs were detected 
in breast, prostate, brain cancer and melanoma. In breast 
cancer the first evidence of  a subpopulation with a spe-
cific cell-surface antigen profile (CD44+/CD24-) that 
can successfully establish itself  as tumor xenograft was 
published in 2003[3]. More recently, aldehyde dehydroge-
nase (ALDH) was used as stem cell marker in 33 human 
breast cell lines[4]. ALDH is a detoxifying enzyme that 
oxidizes intracellular aldehydes and it is thought to play a 
role in the differentiation of  stem cells via the metabolism 
of  retinal to retinoic acid[5]. Interestingly, ALDH activity 
can be used to sort a subpopulation of  cells that display 
stem cell properties from normal breast tissue and breast 
cancer[6]. ALDH activity, assessed by ALDEFLUOR as-
say, has been successfully used to isolate CSCs from mul-
tiple myeloma and acute leukemia as well as from brain 
tumors[7,8]. However in melanoma the ALDH phenotype 
was not associated with more aggressive subpopulations, 
arguing against ALDH as a “universal” marker[9]. 
Another interesting pathway that has been extensively 
studied is the Notch receptor signaling pathway (for a 
recent review see[10]). An important issue is the toxicity 
of  potential treatments against these proteins. Even if  
the Notch pathway appears promising, it is also active in 
normal tissues, thus inhibition of  Notch may have severe 
side effects. Therefore, as suggested by Harrison and col-
leagues, it seems important to study the complexity of  
the Notch pathway to target CSCs more successfully[10]. 
On the other hand, in a recent study, 275 patients 
with primary breast cancers of  different subtypes and 
histological stages were analyzed for CD44+CD24- puta-
tive stem cell marker as well as for other markers (vimen-
tin, osteonectin, connexin 43, ADLH, CK18, GATA3, 
MUC1). This study revealed a high degree of  diversity 
in the expression of  several of  the selected markers in 
different tumor subtypes and histological stages[11]. I 
would like to point out that the latter findings could be 
explained by the fact that none of  these markers are re-
ally specific for CSCs. In glioblastoma multiforme there 
is evidence for the existence of  a more aggressive sub-
population of  cancer cells and several markers have been 
identified[12-14]. Similarly, several candidate populations of  
prostate stem/progenitor cells have been reported includ-
ing those expressing high levels of  CD44, integrin α2β1, 
or CD133[15]. Interestingly, two recent independent stud-
ies in the mouse prostate have identified two different 
populations of  stem cells (SCs). One, marked by CD117 
(c-Kit), seems to be localized in the basal layer[16] and the 
other, called castration-resistant Nkx3.1-expressing cells, 
in the luminal layer[17]. Identification and characterization 
of  normal prostate SCs is clearly relevant to understand-
ing the origin of  human prostate cancer, as suggested by 
recent reviews[14,18]. In fact, it is difficult to ascertain the 
potential overlap and the lineage relationships of  the vari-
ous candidate stem cells that have been identified[19]. This 
is due, in part, to the distinct methodologies and assays 
employed[19]. In melanoma seven papers were published 
from 2005-2008 showing that a CSCs subpopulation ex-
ists[20-25]. However, in 2008 one paper argued against the 
existence of  CSCs, based on the following observations: 
a relatively large fraction of  melanoma cells (up to about 
25%) was shown to initiate tumors in severely immuno-
compromised NOD/SCID IL2Rγnull mice; the fraction 
of  tumor-inducing cells depends upon assay conditions; 
several putative CSC markers appear to be reversibly ex-
pressed[26]. This paper, therefore, suggests that the detec-
tion of  CSCs depends on how severely immunocompro-
mised the mice are. The authors analyzed the expression 
of  more than 50 surface markers on melanoma cells de-
rived from several patients (A2B5, cKIT, CD44, CD49B, 
CD49D, CD49F, CD133, CD166) but focused on CD133 
and CD166[26]. Using these markers they did not find any 
enrichment of  tumor-initiating cells, but always found a 
high frequency of  tumorigenic cells. However, in a recent 
paper it was shown that CD133 is highly expressed in 
melanoma cells and it is not a good marker for sorting 
CSCs[21]. Moreover, in 2010 Boiko and colleagues using 
the same immunocompromised mice could not confirm 
Quintana data[26]. Boiko et al[27] used CD271, a nerve 
growth factor receptor, as marker to identify CSCs.
DO CSCs EXHIST? 
In my view it is quite clear that those involved in the CSC 
field must keep in mind that the only way to show that 
sorted putative CSCs are actually CSCs, is to replicate 
the heterogeneity of  the tumor in syngeneic or immu-
nodeficient mice. While it is possible that more severely 
immunocompromised mice are better than NOD/SCID 
mice, both are models, where the intricate interactions 
with the environment, such as mesenchymal cells, endo-
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thelial cells, and fibroblasts, are lost[1]. Moreover, another 
important issue is the choice markers for sorting CSCs. 
The most common strategy is to use markers that are 
expressed in normal stem cells. However, most of  the 
time the functional role of  these markers in stem cells is 
unknown and their role in stem cell biology is unclear. 
There are two exceptions reported in the literature. One 
is ALDH, which seems to play a specific functional role 
in stem cells[6-8] and the other is CXCR6[28]. ALDH actual-
ly determines cell survival through the ability to detoxify 
many potentially cytotoxic molecules and contributing to 
drug resistance (Figure 1) Several stem cell types, includ-
ing some CSCs, reside in and have metabolic pathways 
attuned to a hypoxic environment and the increase in 
ALDH activity may reflect the demands of  surviving in 
such niches[29]. A recent review summarizes the physi-
ological role of  ALDH[30]. 
The chemokine receptor CXCR6, known as Bonzo, 
STRL33 or TYMSTR is selectively expressed on the sur-
face of  CD4+ T cells, CD8+ T cells[31], NKT cells[32], nat-
ural killer cells[33] and plasma cells[34]. Moreover, CXCR6/
CXCL16 is overexpressed in many cancer cells such as 
breast cancer[35]. CXCR6 is therefore expressed in stem 
cells when they grow asymmetrically and is down regu-
lated when they switch to grow symmetrically[28]. More-
over, CXCR6 was recently shown to be expressed in a 
subpopulation of  melanoma cells with higher self  renewal 
capability[28]. The latest discoveries concerning melanocyte 
stem cells, such as their localization in the hair follicle, is 
discussed in a recent review[36].
An interesting recent paper shows that overexpress-
ing Oct4 cells in human melanoma acquire a stem cell 
phenotype, increasing the expression of  CSC markers[37]. 
This paper raises a number of  new questions that will 
probably be studied in the next few years. In my opinion, 
one of  the most important questions is whether this ef-
fect is caused by all the cells or by a subpopulation, such 
as CSCs.
PERSPECTIVES
I believe that much effort will be required to investigate 
the functional and biological properties of  putative CSCs 
in cancer. Moreover it would be useful to confirm the ex-
pression of  proposed markers in human biopsy samples. 
The development of  diagnostic/prognostic tools to fol-
low cancer development is also a challenge. It would be 
useful to develop a multidisciplinary approach combining 
mathematics, physics and biology, merging experimental 
approaches and theory. In fact, biological models alone 
are not probably able to resolve the problem completely. 
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Figure 1  A generalized ALDH reaction in a living cell.
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